Anixa Biosciences Inc
For the period ended Oct 31, 2025. Filed Jan 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jan 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
The Company has elected not to include a summary pursuant to this Item 16.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Anixa Biosciences, Inc. | ||
| By: | /s/ Amit Kumar | |
| Dr. Amit Kumar | ||
| Chairman of the Board and | ||
| January 12, 2026 | Chief Executive Officer | |
|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
| By: | /s/ Amit Kumar | |
| Dr. Amit Kumar | ||
| Chairman of the Board and | ||
| Chief Executive Officer | ||
| January 12, 2026 | (Principal Executive Officer) | |
|---|---|---|
| By: | /s/ Michael J. Catelani | |
| Michael J. Catelani | ||
| President, Chief Operating Officer and | ||
| Chief Financial Officer | ||
| January 12, 2026 | (Principal Financial and Accounting Officer) | |
| By: | /s/ Lewis H. Titterton, Jr. | |
| Lewis H. Titterton, Jr. | ||
| January 12, 2026 | Director | |
| By: | /s/ Arnold Baskies | |
| Dr. Arnold Baskies | ||
| January 12, 2026 | Director | |
| By: | /s/ Emily Gottschalk | |
| Emily Gottschalk | ||
| January 12, 2026 | Director | |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
OCTOBER 31, 2025
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 200) | F-2 |
|---|---|
| Consolidated Balance Sheets as of October 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations for the years ended October 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Equity for the years ended October 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the years ended October 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
Additional information required by schedules called for under Regulation S-X is either not applicable or is included in the consolidated financial statements or notes thereto.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.